Table 2.
Urinary NGAL levels (NGAL/creatinine; (ng/g)), and associations with various clinical, laboratory and demographic variables. Results are separately reported for the 6-week and 6-month samples. The remaining variables which were tested without significant differences are reported in the Supplementary Materials.
| 6 weeks | P value | 6 months | P value | |||
|---|---|---|---|---|---|---|
| Male | Female | Male | Female | |||
| Donor gender | 18,875 (n = 47) |
23,910 (n = 37) |
0.31 | 12,264 (n = 35) |
21,785 (n = 37) |
0.071 |
| Recipient gender | 18,242 (n = 54) |
37,855 (n = 30) |
0.011 | 11,491 (n = 44) |
32,613 (n = 28) |
0.000 |
| GFRa | R = −0.204 | 0.066 | R = −0.321 | 0.006 | ||
|
| ||||||
| 6 weeks | P value | 6 months | P value | |||
| Not present | Present | Not present | Present | |||
|
| ||||||
| Delayed graft function | 18,875 (n = 13) | 21,315 (n = 71) |
0.218 | 17,554 (n = 45) |
19,354 (n = 27) |
0.866 |
| Isometric vacuolizationb | 19,187 (n = 61) | 31,224 (n = 23) |
0.031 | 22,436 (n = 47) |
9,480 (n = 25) |
0.008 |
| cGrade >0b | 19,031 (n = 70) | 39,575 (n = 14) |
0.033 | 14,218 (n = 44) |
21,115 (n = 28) |
0.583 |
| Urinary tract infection at the time of sampling | 17,901 (n = 63) | 50,548 (n = 14) |
0.000 | 13,760 (n = 56) |
64,889 (n = 6) |
0.014 |
| Panel reactive antibodies at transplantation > 0% | 22,952 (n = 76) |
11,696 (n = 7) |
0.019 | 17,194 (n = 66) |
33,929 (n = 6) |
0.342 |
| Blood transfusion before transplantation | 19,530 (n = 57) |
25,876 (n = 18) |
0.449 | 13,286 (n = 47) |
30,322 (n = 18) |
0.022 |
| MMF in the initial immunosuppression | 27,842 (n = 31) |
19,187 (n = 53) |
0.245 | 24,208 (n = 32) |
17,875 (n = 40) |
0.019 |
| Coronary heart disease before transplantation | 16,502 (n = 70) |
21,822 (n = 14) |
0.116 | 19,354 (n = 61) |
8,969 (n = 11) |
0.043 |
aGFR calculated according to the Cockroft and Gault formula at the time of sampling, baccording to the BANFF classification, at the time of sampling.